Affinia Therapeutics ("Affinia"), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating ...

Retrotransposons are pivotal in human genome evolution, driving structural variation and regulatory innovation while influencing health and disease.

Krystal is leveraging a validated, redosable platform with high margins, profitability, and multiple blockbuster catalysts in CF and NK. Read why KRYS is a Buy.

PDE6A-associated RP, a rare form of inherited retinal disease (IRD), is characterized by nyctalopia, visual field defects, and significant loss of visual acuity (VA). The disease primarily affects the ...

Company plans for additional meetings with the FDA in 1H 2026 to align on a potential accelerated approval pathway for SGT-003 - - INSPIRE DUCHENNE: SGT-003 continues to be generally well tolerated ...

Waltham, Massachusetts Saturday, February 7, 2026, 18:00 Hrs [IST] ...

OGM was selected as a genome-wide, unbiased method to detect large genomic rearrangements and structural variants (SVs) with sensitivity to variant allele fractions (VAFs) as low as 5% to analyze ...

Delivery of therapeutic genes is essential for gene therapy. Adeno-associated viruses (AAVs) are a prime vector for carrying ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...

Alzheimer’s may be driven far more by genetics than previously thought, with one gene playing an outsized role. Researchers found that up to nine in ten cases could be linked to the APOE gene — even ...

The vast dataset allowed the Johns Hopkins University-led team to demonstrate robust connections between specific variations in a mother's DNA and their risk of miscarriage. The findings shed new ...